Connecticut Patent of the Month – March 2024
BioXcel Therapeutics, Inc., a biopharmaceutical company, is combining the power of AI with neuroscience to develop transformative medicines. Recently, the company has been granted a patent for treatments utilizing a non-sedating dexmedetomidine. This approach could redefine the treatment landscape for agitation associated with schizophrenia or bipolar disorder.
Their method involves administering a composition containing a sole active agent, dexmedetomidine or a pharmaceutically acceptable salt thereof, via the oromucosal route to the agitated individual. What’s remarkable about this approach is its precision and effectiveness. By targeting the oromucosal route, the active agent can quickly reach the bloodstream, providing rapid relief from agitation without causing undue sedation.
What sets BioXcel Therapeutics’ invention apart is not just its efficacy but also its safety profile. Traditional treatments often come with significant side effects, particularly cardiovascular complications. BioXcel’s method minimizes these risks, making it a safer alternative for patients.
The invention’s versatility is worth noting. It can be administered in various doses and forms, such as sublingual films, allowing for tailored treatment plans that suit individual patient needs.
The impact of this invention extends beyond just managing agitation. It opens doors for better care and improved quality of life for individuals with schizophrenia or bipolar disorder. By providing rapid relief from agitation without sedation, patients can experience greater comfort and stability in their daily lives.
BioXcel Therapeutics, Inc.’s invention marks a significant advancement in the field of mental health treatment. With its innovative approach, it offers hope for better outcomes and brighter futures for individuals grappling with agitation associated with schizophrenia or bipolar disorder.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
